Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE
    • بيانات النشر:
      Publication: London : Informa Healthcare
      Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]-
    • الموضوع:
      Arthritis, Psoriatic*/drug therapy ; Psoriasis*/chemically induced; Adult ; Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome ; Severity of Illness Index
    • نبذة مختصرة :
      Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of brodalumab for 12 months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort ( n  = 227; PsA, n  = 38) indicated a rapid response to brodalumab treatment within the first 3 months, which was maintained up to 12 months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3 months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum, brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12 months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting.
    • Contributed Indexing:
      Keywords: PsoBest; Psoriasis; brodalumab; psoriatic arthritis; real-world
    • الرقم المعرف:
      6ZA31Y954Z (brodalumab)
      0 (Antibodies, Monoclonal, Humanized)
      0 (Antibodies, Monoclonal)
    • الموضوع:
      Date Created: 20240418 Date Completed: 20240422 Latest Revision: 20240422
    • الموضوع:
      20240422
    • الرقم المعرف:
      10.1080/09546634.2024.2340107
    • الرقم المعرف:
      38636941